{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:43:00Z","timestamp":1772001780826,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jgar.2022.04.025","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T12:00:29Z","timestamp":1651838429000},"page":"378-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Advantages of short-course rifamycin-based regimens for latent tuberculosis infection: an updated network meta-analysis"],"prefix":"10.1016","volume":"29","author":[{"given":"Tzu-Rong","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Hui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeng-Chuan","family":"Shiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-2313","authenticated-orcid":false,"given":"Ming-Chia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-3044","authenticated-orcid":false,"given":"Chih-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jann-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.04.025_bib0001","series-title":"Global tuberculosis report 2021","year":"2021"},{"key":"10.1016\/j.jgar.2022.04.025_bib0002","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ijid.2020.02.021","article-title":"Ending tuberculosis by 2030: pipe dream or reality?","volume":"92s","author":"Chakaya","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2022.04.025_bib0003","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1164\/rccm.201406-1159OC","article-title":"Risk of tuberculosis after recent exposure: a 10-year follow-up study of contacts in Amsterdam","volume":"190","author":"Sloot","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2022.04.025_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0950268897007917","article-title":"The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection","volume":"119","author":"Vynnycky","year":"1997","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jgar.2022.04.025_bib0006","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jgar.2022.04.025_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jgar.2022.04.025_bib0008","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection: a network meta-analysis","volume":"161","author":"Stagg","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0009","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","article-title":"Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses","volume":"17","author":"Pease","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2022.04.025_bib0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0011","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0012","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2022.04.025_bib0013","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0014","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jgar.2022.04.025_bib0015","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0016","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0962-8479(96)90007-6","article-title":"Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial","volume":"77","author":"Cowie","year":"1996","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.jgar.2022.04.025_bib0017","first-page":"419","article-title":"The use of isoniazid among household contacts of open cases of pulmonary tuberculosis","volume":"33","author":"Egsmose","year":"1965","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jgar.2022.04.025_bib0018","first-page":"300","article-title":"Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial","volume":"25","author":"Geijo","year":"2007","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica"},{"key":"10.1016\/j.jgar.2022.04.025_bib0019","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.283.11.1445","volume":"283","author":"Gordin","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2022.04.025_bib0020","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(97)06532-X","article-title":"Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection","volume":"351","author":"Halsey","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2022.04.025_bib0021","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","year":"1982","journal-title":"International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ"},{"key":"10.1016\/j.jgar.2022.04.025_bib0022","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5588\/ijtld.12.0510","article-title":"Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population","volume":"17","author":"Jim\u00e9nez-Fuentes","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jgar.2022.04.025_bib0023","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200111090-00009","article-title":"Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults","volume":"15","author":"Johnson","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2022.04.025_bib0024","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/jac\/dku562","article-title":"Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-\u03b3-releasing assay: an exploratory randomized controlled trial","volume":"70","author":"Kim","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.04.025_bib0025","first-page":"401","article-title":"Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis","volume":"111","author":"Mart\u00ednez Alfaro","year":"1998","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jgar.2022.04.025_bib0026","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0025-7753(00)71496-5","article-title":"Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group","volume":"115","author":"Mart\u00ednez Alfaro","year":"2000","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jgar.2022.04.025_bib0027","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0028","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0029","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0030","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts","volume":"173","author":"Schechter","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0031","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0032","first-page":"276","article-title":"Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?","volume":"9","author":"Tortajada","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jgar.2022.04.025_bib0033","first-page":"169","article-title":"Long term isoniazid prophylaxis: controlled trial on INH prophylaxis after recent tuberculin conversion in young adults","volume":"41","author":"Veening","year":"1968","journal-title":"Bull Int Union Tuberc"},{"key":"10.1016\/j.jgar.2022.04.025_bib0034","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1378\/chest.124.6.2112","article-title":"Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong","volume":"124","author":"Leung","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jgar.2022.04.025_bib0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1157\/13102265","article-title":"Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients","volume":"25","author":"Rivero","year":"2007","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica"},{"key":"10.1016\/j.jgar.2022.04.025_bib0036","first-page":"62","article-title":"Treatment of latent tuberculosis infection in injecting drug users co-infected by HIV","volume":"4","author":"Sanchez","year":"2002","journal-title":"Enfermedades Emergentes"},{"key":"10.1016\/j.jgar.2022.04.025_bib0037","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0038","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1714284","article-title":"Safety and side effects of rifampin versus isoniazid in children","volume":"379","author":"Diallo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0039","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01470-2018","article-title":"Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study","volume":"52","author":"Gao","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2022.04.025_bib0040","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.04.025_bib0041","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tube.2018.05.013","article-title":"Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicentre randomised controlled trial in Taiwan","volume":"111","author":"Sun","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.jgar.2022.04.025_bib0042","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12879-021-05766-9","article-title":"An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study","volume":"21","author":"Surey","year":"2021","journal-title":"BMC Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:27Z","timestamp":1761991167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":42,"alternative-id":["S2213716522001047"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.04.025","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advantages of short-course rifamycin-based regimens for latent tuberculosis infection: an updated network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}